Selecta Biosciences' Dr. Carsten Brunn On Gene Therapy With AAV Vectors
Source: Cell & Gene
Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies.
This website uses cookies to ensure you get the best experience on our website. Learn more